Profilo
Frank DeRosa worked as a Senior Director of Preclinical Research at Shire Human Genetic Therapies, Inc. from 2009 to 2016.
He then worked as the Chief Technology Officer at Translate Bio, Inc. from 2019 to 2021.
Prior to his career in industry, he earned a doctorate degree from the University of California.
Precedenti posizioni note di Frank DeRosa
Società | Posizione | Fine |
---|---|---|
TRANSLATE BIO, INC. | Direttore Tecnico/Scientifico/R&S | 14/09/2021 |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Corporate Officer/Principal | 01/12/2016 |
Formazione di Frank DeRosa
University of California | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Translate Bio, Inc.
Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Health Technology |
- Borsa valori
- Insiders
- Frank DeRosa